Vaccination remains the best strategy against coronavirus disease 2019 (COVID-19) in terms of prevention. The efficacy and safety of COVID-19 vaccines is supported by well-designed clinical trials that recruited many participants. It is well-known that vaccination is associated with local side effects related to the injection site, and mild, systemic side effects. However, there has been an increase in the occurrence of what is known as infrequent adverse effects in the population of vaccinated individuals in real life. We present the case of a 46-year-old woman with no past medical history, who presented with a sharp chest pain with deep inspiration, a few days after receiving the third dose of the Pfizer-BioNTech COVID-19 mRNA vaccine (BNT162b2). There is an association between the BNT16b2 vaccination and myocarditis, pericarditis, and even bilateral pleural effusions. To the best of our knowledge, this is the first report featuring a unilateral pleural effusion in a patient with no known past medical history, who did not develop cardiac involvement nor have any viral infection. The aim of our report is to inform health professionals of the possibility of encountering this rare adverse event in their daily practice, as the population of individuals who are receiving additional vaccine doses is increasing steadily.
More than 25% of asthmatics worldwide are current or former smokers. Smoking in asthma leads to suboptimal control, lower quality of life and frequent exacerbations. Despite that there is lack of evidence concerning the treatment of smoking asthmatics, this large population is usually excluded from studies. All RCTs with triple therapy in asthma exvluded smokers more than 10p/y. The aim of our study was to determine if current or former smokers (>10p/y) with uncontrolled asthma (good inhalation technique and adherence, treated co morbidities) could benefit from the addition of LAMA to their treatment with (medium or high dose)ICS/LABA. We excluded patients with COPD, bronchiectasis, severe heart failure and other severe comorbidities. and conducted a single arm trial, adding LAMA for 3 months. Our primary end point was FEV1. Secondary end points were ACT, AQOL and HADS scale. We included 22 smokers and conducted a single arm trial, adding LAMA for 3 m. Results are shown in Fig 2 We conclude that even asthmatic that smoke more than 10py benefit from the addition of LAMA. More research with RCTS is needed in order to prove efficasy of adding LAMA in smoking asthmatics stage 4-5.